Ibrutinib Combined with Gemcitabine-vinorelbine for Primary Refractory Non-Hodgkin Lymphoma

Overview

Journal Blood Res

Publisher Springer Nature

Specialty Hematology

Date 2023 Nov 15

PMID 37964656

Authors

Muruvvet Seda Aydin

Esra Cengiz

Ferda Can

Simten Dagdas

Imdat Dilek

Gulsum Ozet

Affiliations

Soon will be listed here.

References

Wilson W, Phillips T, Popplewell L, de Vos S, Chhabra S, Kimball A . Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021; 62(9):2094-2106. PMC: 9907362. DOI: 10.1080/10428194.2021.1907371. View

Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R . Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019; 26(4):253-265. PMC: 6726277. DOI: 10.3747/co.26.5421. View

Sivam V, Cook L, Hughes G, Karadimitris A, Marks A, Matthey F . Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma. Hematol Oncol. 2012; 30(4):214-5. DOI: 10.1002/hon.2011. View

Petrackova A, Turcsanyi P, Papajik T, Kriegova E . Revisiting Richter transformation in the era of novel CLL agents. Blood Rev. 2021; 49:100824. DOI: 10.1016/j.blre.2021.100824. View

Maddocks K, Christian B, Jaglowski S, Flynn J, Jones J, Porcu P . A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2014; 125(2):242-8. DOI: 10.1182/blood-2014-08-597914. View

Hou K, Yu Z, Jia Y, Fang H, Shao S, Huang L . Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. Crit Rev Oncol Hematol. 2020; 152:103010. DOI: 10.1016/j.critrevonc.2020.103010. View

Kesireddy M, Lunning M . Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused". Oncology (Williston Park). 2022; 36(6):366-375. DOI: 10.46883/2022.25920963. View

Sauter C, Matasar M, Schoder H, Devlin S, Drullinsky P, Gerecitano J . A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018; 131(16):1805-1808. PMC: 5909762. DOI: 10.1182/blood-2017-08-802561. View

Thompson P, Siddiqi T . Treatment of Richter's syndrome. Hematology Am Soc Hematol Educ Program. 2022; 2022(1):329-336. PMC: 9820569. DOI: 10.1182/hematology.2022000345. View

10.

Mamgain G, Singh P, Patra P, Naithani M, Nath U . Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment. J Family Med Prim Care. 2022; 11(8):4151-4158. PMC: 9638643. DOI: 10.4103/jfmpc.jfmpc_2432_21. View

11.

Zhou Z, Zhang L, Wang X, Li X, Li L, Fu X . Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Ann Hematol. 2021; 100(6):1509-1516. DOI: 10.1007/s00277-021-04535-7. View